Hjem › Tripelnegativ brystkreft › Missouri › St. Louis
Kliniske studier for Tripelnegativ brystkreft i St. Louis, MO
21 studier for Tripelnegativ brystkreft søker deltakere på steder i og rundt St. Louis (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekruttererFase 1
- Washington University Medicine, St Louis
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruttererFase 1
- Washington University School of Medicine in St. Louis, St Louis
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
RekruttererFase 1/2
- Washington University, St Louis
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekruttererObservasjonsstudie
- Washington University, St Louis
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RekruttererFase 3
- Siteman Cancer Center ( Site 0099), St Louis
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RekruttererFase 3
- Washington University Siteman Cancer Center ( Site 0031), St Louis
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RekruttererFase 1/2
- Local Institution - 0140, St Louis
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- Washington University, St Louis
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
RekruttererFase 2
- Washington University School of Medicine, St Louis
- Siteman Cancer Center-South County, St Louis
- Siteman Cancer Center at Christian Hospital, St Louis
- og 1 flere
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekruttererFase 3
- Washington University School of Medicine, St Louis
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
RekruttererObservasjonsstudie
- Cancer Care Specialist of Illinois, O'Fallon · 16 mi unna
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RekruttererFase 1
- Washington University, St Louis
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- Research Site, St Louis
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RekruttererFase 1
- Normunity Investigational Site, St Louis
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
RekruttererFase 1
- Washington University School of Medicine, St Louis
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
RekruttererObservasjonsstudie
- Mercy Hospital - South, St Louis
- Mercy Hospital -STL, St Louis
A Study of LY4175408 in Participants With Advanced Cancer
RekruttererFase 1
- Washington University, St Louis
Study of XB010 in Subjects With Solid Tumors
RekruttererFase 1
- Siteman Cancer Center, St Louis
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
RekruttererFase 1/2
- Siteman Cancer Center, St Louis
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RekruttererFase 1/2
- Washington University, St Louis
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RekruttererFase 1/2
- Washington University, St Louis
Tripelnegativ brystkreft-studier i andre byer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
- Grand Rapids, MI15 studier
Andre studier i St. Louis
- Ikke-småcellet lungekreft73 studier
- Brystkreft64 studier
- Metastatisk kreft54 studier
- Kolorektal kreft50 studier
- Kreft (alle typer)46 studier
- Prostatakreft46 studier
- Lungekreft39 studier
- Eggstokkreft38 studier
- Pankreaskreft33 studier
- Endometriekreft29 studier
- Plateepitelcancer i hode og hals28 studier
- Hjertesvikt26 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.